Cargando…
Major adverse cardiac events and drug-coated balloon size in coronary interventions
OBJECTIVE: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kare Publishing
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998862/ https://www.ncbi.nlm.nih.gov/pubmed/29848922 http://dx.doi.org/10.14744/AnatolJCardiol.2018.67864 |
_version_ | 1783331316396195840 |
---|---|
author | Naguib, David Knoop, Betül Dannenberg, Lisa Liebsch, Eva Pöhl, Martin Helten, Carolin Assadi-Schmidt, Athena Kelm, Malte Zeus, Tobias Polzin, Amin |
author_facet | Naguib, David Knoop, Betül Dannenberg, Lisa Liebsch, Eva Pöhl, Martin Helten, Carolin Assadi-Schmidt, Athena Kelm, Malte Zeus, Tobias Polzin, Amin |
author_sort | Naguib, David |
collection | PubMed |
description | OBJECTIVE: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the vessel wall; however, they are associated with a higher lesion length and vessel injury. Hypothesis: DCB length is associated with clinical outcome. METHODS: We analyzed 286 consecutive Pantera Lux (Biotronik, active component Paclitaxel) DCB-treated patients between April 2009 and June 2012. Of them, 176 patients were treated using a 15-mm DCB and 109 were treated using a 20-mm DCB. Baseline characteristics and major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during initial hospital stay and a 2-year follow-up period were obtained. RESULTS: Patients characteristics such as cardiovascular risk factors, prior diseases, co-medication, clinical presentation, target vessel, and left ventricular function did not differ between the groups. MACE during hospital course was similar [1.7% vs. 2.8%, relative risk (RR) 1.6, 95% confidence interval (CI) 0.3-7.9, p=0.554]. Likewise, at 2-year follow-up, MACE did not differ between the groups (23.2% vs. 27.5%, RR 1.2, 95% CI 0.6-1.5, p=0.408). CONCLUSION: DCB length was not associated with clinical outcome during a 2-year follow-up period. |
format | Online Article Text |
id | pubmed-5998862 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Kare Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-59988622018-06-18 Major adverse cardiac events and drug-coated balloon size in coronary interventions Naguib, David Knoop, Betül Dannenberg, Lisa Liebsch, Eva Pöhl, Martin Helten, Carolin Assadi-Schmidt, Athena Kelm, Malte Zeus, Tobias Polzin, Amin Anatol J Cardiol Original Investigation OBJECTIVE: In-stent restenosis (ISR) is a feared complication after coronary stent implantation. Drug-coated balloon (DCB) is being promoted as a treatment option for ISR. However, the benefit-risk ratio of DCB length has not been investigated. Longer DCBs release more anti-proliferative drug to the vessel wall; however, they are associated with a higher lesion length and vessel injury. Hypothesis: DCB length is associated with clinical outcome. METHODS: We analyzed 286 consecutive Pantera Lux (Biotronik, active component Paclitaxel) DCB-treated patients between April 2009 and June 2012. Of them, 176 patients were treated using a 15-mm DCB and 109 were treated using a 20-mm DCB. Baseline characteristics and major adverse cardiac events (MACE; death, myocardial infarction, and target lesion revascularization) during initial hospital stay and a 2-year follow-up period were obtained. RESULTS: Patients characteristics such as cardiovascular risk factors, prior diseases, co-medication, clinical presentation, target vessel, and left ventricular function did not differ between the groups. MACE during hospital course was similar [1.7% vs. 2.8%, relative risk (RR) 1.6, 95% confidence interval (CI) 0.3-7.9, p=0.554]. Likewise, at 2-year follow-up, MACE did not differ between the groups (23.2% vs. 27.5%, RR 1.2, 95% CI 0.6-1.5, p=0.408). CONCLUSION: DCB length was not associated with clinical outcome during a 2-year follow-up period. Kare Publishing 2018-06 2018-05-22 /pmc/articles/PMC5998862/ /pubmed/29848922 http://dx.doi.org/10.14744/AnatolJCardiol.2018.67864 Text en Copyright: © 2018 Turkish Society of Cardiology http://creativecommons.org/licenses/by-nc-sa/4.0 This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License |
spellingShingle | Original Investigation Naguib, David Knoop, Betül Dannenberg, Lisa Liebsch, Eva Pöhl, Martin Helten, Carolin Assadi-Schmidt, Athena Kelm, Malte Zeus, Tobias Polzin, Amin Major adverse cardiac events and drug-coated balloon size in coronary interventions |
title | Major adverse cardiac events and drug-coated balloon size in coronary interventions |
title_full | Major adverse cardiac events and drug-coated balloon size in coronary interventions |
title_fullStr | Major adverse cardiac events and drug-coated balloon size in coronary interventions |
title_full_unstemmed | Major adverse cardiac events and drug-coated balloon size in coronary interventions |
title_short | Major adverse cardiac events and drug-coated balloon size in coronary interventions |
title_sort | major adverse cardiac events and drug-coated balloon size in coronary interventions |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998862/ https://www.ncbi.nlm.nih.gov/pubmed/29848922 http://dx.doi.org/10.14744/AnatolJCardiol.2018.67864 |
work_keys_str_mv | AT naguibdavid majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT knoopbetul majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT dannenberglisa majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT liebscheva majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT pohlmartin majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT heltencarolin majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT assadischmidtathena majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT kelmmalte majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT zeustobias majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions AT polzinamin majoradversecardiaceventsanddrugcoatedballoonsizeincoronaryinterventions |